Published in Eur J Neurosci on June 01, 2005
The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention. Neurochem Int (2007) 2.11
The role of astroglia in neuroprotection. Dialogues Clin Neurosci (2009) 1.14
Astrocyte pathology in the prefrontal cortex impairs the cognitive function of rats. Mol Psychiatry (2014) 0.87
Glutamate uptake block triggers deadly rhythmic bursting of neonatal rat hypoglossal motoneurons. J Physiol (2006) 0.85
Ceftriaxone increases glutamate uptake and reduces striatal tyrosine hydroxylase loss in 6-OHDA Parkinson's model. Mol Neurobiol (2013) 0.80
Old Things New View: Ascorbic Acid Protects the Brain in Neurodegenerative Disorders. Int J Mol Sci (2015) 0.76
Evidence for change in current-flux coupling of GLT1 at high glutamate concentrations in rat primary forebrain neurons and GLT1a-expressing COS-7 cells. Eur J Neurosci (2009) 0.76
GLT-1 Transport Stoichiometry Is Constant at Low and High Glutamate Concentrations when Chloride Is Substituted by Gluconate. PLoS One (2015) 0.75
Glutamate transporters in brain ischemia: to modulate or not? Acta Pharmacol Sin (2014) 0.75
Nicotinic receptor activation contrasts pathophysiological bursting and neurodegeneration evoked by glutamate uptake block on rat hypoglossal motoneurons. J Physiol (2016) 0.75
Calcineurin/NFAT signaling in activated astrocytes drives network hyperexcitability in Aβ-bearing mice. J Neurosci (2017) 0.75
Gene expression analyses reveal molecular relationships among 20 regions of the human CNS. Neurogenetics (2006) 3.40
Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) distribution in spinal cord and dorsal root ganglia under basal and neuropathic pain conditions. Eur J Neurosci (2004) 2.11
Screening technologies for ion channel drug discovery. Future Med Chem (2010) 1.58
Corticotropin releasing hormone type 2 receptors in the dorsal raphe nucleus mediate the behavioral consequences of uncontrollable stress. J Neurosci (2003) 1.53
A cog in cognition: how the alpha 7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits. Pharmacol Ther (2009) 1.31
Neuronal nicotinic acetylcholine receptors - targets for the development of drugs to treat cognitive impairment associated with schizophrenia and Alzheimer's disease. Curr Top Med Chem (2010) 1.21
Antiobesity-like effects of the 5-HT2C receptor agonist WAY-161503. Brain Res (2006) 1.15
Test-retest stability analysis of resting brain activity revealed by blood oxygen level-dependent functional MRI. J Magn Reson Imaging (2012) 1.09
Pharmacological evidence supporting a role for central corticotropin-releasing factor(2) receptors in behavioral, but not endocrine, response to environmental stress. J Pharmacol Exp Ther (2002) 1.09
Amiloride is neuroprotective in an MPTP model of Parkinson's disease. Neurobiol Dis (2008) 1.07
Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents. ACS Chem Neurosci (2014) 1.06
High-affinity CRF1 receptor antagonist NBI-34041: preclinical and clinical data suggest safety and efficacy in attenuating elevated stress response. Neuropsychopharmacology (2007) 1.06
Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells. Am J Pathol (2002) 1.04
Behavioral characterization of A53T mice reveals early and late stage deficits related to Parkinson's disease. PLoS One (2013) 1.03
Behavioral and neuroendocrine effects of the selective CRF2 receptor agonists urocortin II and urocortin III. Peptides (2004) 1.03
Tinea gladiatorum: Pennsylvania's experience. Clin J Sport Med (2002) 1.02
Peripheral administration of the melanocortin-4 receptor antagonist NBI-12i ameliorates uremia-associated cachexia in mice. J Am Soc Nephrol (2007) 1.02
hERG (KCNH2 or Kv11.1) K+ channels: screening for cardiac arrhythmia risk. Curr Drug Metab (2008) 1.02
Voltage- and Temperature-Dependent Allosteric Modulation of α7 Nicotinic Receptors by PNU120596. Front Pharmacol (2011) 1.02
Aligning strategies for using EEG as a surrogate biomarker: a review of preclinical and clinical research. Biochem Pharmacol (2010) 1.02
Ligand dependency of 5-hydroxytryptamine 2C receptor internalization. J Pharmacol Exp Ther (2004) 1.00
Targeting the cholinergic system as a therapeutic strategy for the treatment of pain. Neuropharmacology (2007) 1.00
Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders. J Pharmacol Exp Ther (2009) 0.99
Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. J Neurochem (2013) 0.99
Indiplon is a high-affinity positive allosteric modulator with selectivity for alpha1 subunit-containing GABAA receptors. J Pharmacol Exp Ther (2006) 0.99
Functional properties of alpha7 nicotinic acetylcholine receptors co-expressed with RIC-3 in a stable recombinant CHO-K1 cell line. Assay Drug Dev Technol (2008) 0.94
Neuroprotective effects of insulin-like growth factor-binding protein ligand inhibitors in vitro and in vivo. J Cereb Blood Flow Metab (2003) 0.94
Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents. Psychopharmacology (Berl) (2007) 0.94
Racial differences in the interaction between family history and risk factors associated with diabetes in the National Health and Nutritional Examination Survey, 1999-2004. Genet Med (2009) 0.93
Prioritized research recommendations from the National Institute of Neurological Disorders and Stroke Parkinson's Disease 2014 conference. Ann Neurol (2014) 0.92
The regulation of feeding and metabolic rate and the prevention of murine cancer cachexia with a small-molecule melanocortin-4 receptor antagonist. Endocrinology (2005) 0.92
Acid sensing ion channel (ASIC) inhibitors exhibit anxiolytic-like activity in preclinical pharmacological models. Psychopharmacology (Berl) (2008) 0.92
A novel cell-based assay for G-protein-coupled receptor-mediated cyclic adenosine monophosphate response element binding protein phosphorylation. J Biomol Screen (2006) 0.91
A conservative, single-amino acid substitution in the second cytoplasmic domain of the human Serotonin2C receptor alters both ligand-dependent and -independent receptor signaling. J Pharmacol Exp Ther (2007) 0.91
Direct inhibition of Ih by analgesic loperamide in rat DRG neurons. J Neurophysiol (2007) 0.91
Human class-I restricted T cell associated molecule is highly expressed in the cerebellum and is a marker for activated NKT and CD8+ T lymphocytes. J Neuroimmunol (2005) 0.90
The four major N- and C-terminal splice variants of the excitatory amino acid transporter GLT-1 form cell surface homomeric and heteromeric assemblies. Mol Pharmacol (2009) 0.90
Characterization of novel selective H1-antihistamines for clinical evaluation in the treatment of insomnia. J Med Chem (2009) 0.90
Evaluation of FLIPR Calcium 3 Assay Kit--a new no-wash fluorescence calcium indicator reagent. J Biomol Screen (2003) 0.89
Comparison of reprogramming efficiency between transduction of reprogramming factors, cell-cell fusion, and cytoplast fusion. Stem Cells (2010) 0.88
The metabotropic glutamate receptor 7 allosteric modulator AMN082: a monoaminergic agent in disguise? J Pharmacol Exp Ther (2011) 0.87
mGlu4 potentiation of K(2P)2.1 is dependant on C-terminal dephosphorylation. Mol Cell Neurosci (2007) 0.87
Current technology for the derivation of pluripotent stem cell lines from human embryos. Cell Stem Cell (2010) 0.86
5-HT2C receptor agonists as an innovative approach for psychiatric disorders. Drug News Perspect (2007) 0.86
Characterization of the 5-HT6 receptor coupled to Ca2+ signaling using an enabling chimeric G-protein. Eur J Pharmacol (2003) 0.85
Molecular interactions of nonpeptide agonists and antagonists with the melanocortin-4 receptor. Biochemistry (2005) 0.85
The role of transmembrane helix 5 in agonist binding to the human H3 receptor. J Pharmacol Exp Ther (2002) 0.85
5-HT(2C) agonists as therapeutics for the treatment of schizophrenia. Handb Exp Pharmacol (2012) 0.84
Inhibition of glucosylceramide synthase stimulates autophagy flux in neurons. J Neurochem (2014) 0.84
Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors. Bioorg Med Chem Lett (2008) 0.83
Pyrrolidinones as orally bioavailable antagonists of the human melanocortin-4 receptor with anti-cachectic activity. Bioorg Med Chem (2007) 0.83
Effects of a selective agonist and antagonist of CRF2 receptors on cardiovascular function in the rat. Eur J Pharmacol (2003) 0.83
Pharmacological and pharmacokinetic characterization of 2-piperazine-alpha-isopropyl benzylamine derivatives as melanocortin-4 receptor antagonists. Bioorg Med Chem (2008) 0.83
The C-terminus of Gi family G-proteins as a determinant of 5-HT(1A) receptor coupling. Biochem Biophys Res Commun (2002) 0.83
Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms. Biochem Pharmacol (2005) 0.82
Identification of differentially expressed genes induced by transient ischemic stroke. Brain Res Mol Brain Res (2002) 0.82
Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors. Bioorg Med Chem Lett (2008) 0.82
Characterization of the interaction of indiplon, a novel pyrazolopyrimidine sedative-hypnotic, with the GABAA receptor. J Pharmacol Exp Ther (2004) 0.81
Over-expression of the human EAAT2 glutamate transporter within neurons of mouse organotypic hippocampal slice cultures leads to increased vulnerability of CA1 pyramidal cells. Eur J Neurosci (2005) 0.81
Cycloalkyl[b][1,4]benzodiazepinoindoles are agonists at the human 5-HT2C receptor. Bioorg Med Chem Lett (2004) 0.81
Novel pharmacological activity of loperamide and CP-339,818 on human HCN channels characterized with an automated electrophysiology assay. Eur J Pharmacol (2007) 0.80
Pituitary adenylate cyclase-activating peptide (PACAP) induces differentiation in the neuronal F11 cell line through a PKA-dependent pathway. Brain Res (2006) 0.80
Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor. Bioorg Med Chem Lett (2007) 0.80
Corticotropin-releasing factor: effect on cerebral blood flow in physiologic and ischaemic conditions. Exp Brain Res (2005) 0.80
Purinergic receptor-mediated morphological changes in microglia are transient and independent from inflammatory cytokine release. Eur J Pharmacol (2010) 0.80
Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia. Bioorg Med Chem Lett (2010) 0.79
Validation of DRG-like F11 cells for evaluation of KCNQ/M-channel modulators. Assay Drug Dev Technol (2006) 0.79
Identification of a novel selective H1-antihistamine with optimized pharmacokinetic properties for clinical evaluation in the treatment of insomnia. Bioorg Med Chem Lett (2010) 0.79
Functional calcium coupling with the human metabotropic glutamate receptor subtypes 2 and 4 by stable co-expression with a calcium pathway facilitating G-protein chimera in Chinese hamster ovary cells. Biochem Pharmacol (2003) 0.78
Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia. Bioorg Med Chem Lett (2009) 0.78
Synthesis and biological activities of aryl-ether-, biaryl-, and fluorene-aspartic acid and diaminopropionic acid analogs as potent inhibitors of the high-affinity glutamate transporter EAAT-2. Bioorg Med Chem Lett (2005) 0.78
Screening of immunophilin ligands by quantitative analysis of neurofilament expression and neurite outgrowth in cultured neurons and cells. J Neurosci Methods (2007) 0.78
Design, synthesis, in vitro, and in vivo characterization of phenylpiperazines and pyridinylpiperazines as potent and selective antagonists of the melanocortin-4 receptor. J Med Chem (2007) 0.78
Identification and characterization of pyrrolidine diastereoisomers as potent functional agonists and antagonists of the human melanocortin-4 receptor. Bioorg Med Chem Lett (2007) 0.78
Preclinical assessment of an adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914/SEN34625. Psychopharmacology (Berl) (2011) 0.78
SAR and biological evaluation of SEN12333/WAY-317538: Novel alpha 7 nicotinic acetylcholine receptor agonist. Bioorg Med Chem (2009) 0.78
Design and synthesis of 3-arylpyrrolidine-2-carboxamide derivatives as melanocortin-4 receptor ligands. Bioorg Med Chem Lett (2008) 0.78
Development of an improved IP(1) assay for the characterization of 5-HT(2C) receptor ligands. Assay Drug Dev Technol (2010) 0.78
Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain. J Med Chem (2008) 0.77
Piperazinebenzylamines as potent and selective antagonists of the human melanocortin-4 receptor. Bioorg Med Chem Lett (2004) 0.77
Scintillation proximity assay in lead discovery. Expert Opin Drug Discov (2008) 0.77
Potent and orally active non-peptide antagonists of the human melanocortin-4 receptor based on a series of trans-2-disubstituted cyclohexylpiperazines. Bioorg Med Chem Lett (2005) 0.77
WAY-100635 antagonist-induced plasticity of 5-HT receptors: regulatory differences between a stable cell line and an in vivo native system. J Neurochem (2006) 0.77
Validation of a medium-throughput electrophysiological assay for KCNQ2/3 channel enhancers using IonWorks HT. J Biomol Screen (2007) 0.77
Ischemic preconditioning reduces infarct volume after subdural hematoma in the rat. Brain Res (2002) 0.77
Phenylguanidines as selective nonpeptide melanocortin-5 receptor antagonists. J Med Chem (2004) 0.76